Apricus Biosciences Inc (NASDAQ:APRI)
| 3.30 Data as of May 22 |  -0.11 / -3.23%Today’s Change | 1.89 Today|||52-Week Range 3.63 | +65.83% Year-to-Date |
Latest APRI News | Press Releases
No recent news for Apricus Biosciences Inc.
Today’s Trading
| Previous close | 3.41 |
| Today’s open | 3.43 |
| Day’s range | -- - -- |
| Volume | 657,170 |
| Average volume (3 months) | 206,277 |
| Market cap | $104.1M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/22/2013
Growth & Valuation
| Earnings growth (last year) | -28.89% |
| Earnings growth (this year) | +43.01% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +105.21% |
| P/E ratio | NM |
| Price/Sales | 6.49 |
| Price/Book | 15.42 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ATHXAthersys Inc | 0.00 | 0.00% |
| BOTABiota Pharmaceutical... | -0.04 | -1.08% |
| ACURAcura Pharmaceutical... | +0.04 | +1.74% |
| NNVCNanoViricides Inc | +0.08 | +13.10% |
Data as of 4:00pm ET, 05/22/2013
Financials
| Last reporting date | May 13, 2013 |
| EPS forecast (this quarter) | -$0.24 |
| Annual revenue (last year) | $8.4M |
| Annual profit (last year) | -$31.8M |
| Net profit margin | -303.71% |
Profile
Sector Health Technology |
Industry Medical Specialties |
Chief Executive Officer & Director Richard W. Pascoe |
Chief Financial Officer & Senior Vice President Steven Robert Martin, CPA |
Corporate headquarters San Diego, California |
Forecasts
